You are here: Home » Companies » News
Business Standard

Shilpa Medicare gets USFDA approval for cancer treatment injection

Shilpa Medicare said the US market for Irinotecan HCL is approximately $18 million

Press Trust of India  |  New Delhi 

The company already enjoys a 67-68 per cent share of the respiratory drugs market in India and has potential for a 14-15 per cent growth

Shilpa on Tuesday said it has received approval from the US health regulator for HCL injection, used for treatment of certain kind of

The company has received (USFDA) approval for its ANDA HCL injection USP in the strengths 40 mg/2mL and 100 mg/5mL (20mg/mL) single dose vials, Shilpa said in a BSE filing.

injection is used in the treatment of patients with of the colon or rectum, the company added.

Quoting IQVIA MAT second quarter 2018 data, Shilpa said the US market for Irinotecan HCL is approximately $18 million.

Shares of were trading 3.80 per cent up at Rs 398.65 apiece on BSE.

First Published: Tue, January 01 2019. 12:05 IST
RECOMMENDED FOR YOU